TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.
Revenue (Most Recent Fiscal Year) | $233.66M |
Net Income (Most Recent Fiscal Year) | $12.67M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | 699.00 |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 9.25 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 13.19 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 159.91 |
Pre-Tax Margin (Trailing 12 Months) | 5.59% |
Net Margin (Trailing 12 Months) | 5.42% |
Return on Equity (Trailing 12 Months) | 12.89% |
Return on Assets (Trailing 12 Months) | 4.70% |
Current Ratio (Most Recent Fiscal Quarter) | 5.92 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.18 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.62 |
Inventory Turnover (Trailing 12 Months) | 0.43 |
Book Value per Share (Most Recent Fiscal Quarter) | $1.06 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
Earnings per Share (Most Recent Fiscal Year) | $0.09 |
Diluted Earnings per Share (Trailing 12 Months) | $0.02 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 154.54M |
Free Float | 140.32M |
Market Capitalization | $2.16B |
Average Volume (Last 20 Days) | 2.50M |
Beta (Past 60 Months) | 2.30 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 9.20% |
Percentage Held By Institutions (Latest 13F Reports) | 58.58% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |